Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar
scientific article published on 05 June 2018
Author/s
author: Giuseppe Alberto Palumbo, Nicola Polverelli, Elisabetta Abruzzese, Mario Tiribelli, Florian H Heidel, Massimiliano Bonifacio, Micaela Bergamaschi, Alessia Tieghi, Monica Crugnola, Francesco Cavazzini, Gianni Binotto, Alessandro Isidori, Nicola Sgherza, Costanza Bosi, Giuseppe Auteri, Luigi Scaffidi, Malgorzata Monika Trawinska, Daniele Cattaneo, Lucia Catani, Roberto M Lemoli, Antonio Cuneo, Francesco Di Raimondo, Michele Cavo, Roberto Latagliata, Giulia Benevolo, Mariella D'Adda, Francesca Palandri, Adalberto Ibatici, Massimo Breccia, Giampietro Semenzato, Daniela Bartoletti, Francesco Soci, Domenico Penna
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.